CANFNYSEPharmaceutical PreparationsFiscal year ends December 31
Can-Fite BioPharma Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$1.89+0.13 (+7.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Operating margin
-2456.8%−603.7 pts over 5 years
Net margin
-2426.7%−533.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -39.9% | -20.6% | -11.9% | +9.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -339.2% | -178.2% | |
| Return on assets | – | -163.2% | -105.5% | |
| Current ratio | 3.30 | 7.41 | 3.46 | |
| Interest coverage | -157.9× | – | -35.0× | |
| Capex to revenue | 6.1% | 3.4% | 0.5% | |
| Diluted shares | 0M | 0M | 2M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Can-Fite BioPharma generated $45.69M from operations and spent $2.62M on capital expenditure, dividends and share buybacks. 1% of that went back into the business.
Generated
$45.69M
Used
$2.62M
Capital expenditure$29.00K1%Dividends$2.59M99%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2426.7%
×Asset turnover0.04×
×Equity multiplier1.69×
=Return on equity, FY2025-178.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -2426.7% | 0.04× | 1.69× | -178.2% |
| FY2024 | -1169.1% | 0.07× | 1.64× | -134.9% |
| FY2023 | -1027.5% | 0.08× | 1.80× | -142.5% |
| FY2022 | -1255.9% | 0.05× | 1.57× | -107.9% |
| FY2021 | -1478.9% | 0.06× | 1.46× | -123.3% |
| FY2020 | -1892.9% | 0.09× | 2.08× | -339.2% |
| FY2019 | -621.3% | 0.25× | 2.96× | -462.7% |
| FY2018 | -172.0% | 0.49× | 2.59× | -219.1% |
| FY2017 | -613.7% | 0.09× | 2.00× | -108.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$9.83M
- Cash generatingOperating cash flow above zero-$8.95M
- Return on assets improvedROA up on the prior year-78.9% → -107.8%
- Earnings backed by cashOperating cash flow above net income-$8.95M vs -$9.83M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.38 → 3.46
- No dilutionShare count did not rise1M → 2M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.07 → 0.04